Cardio Diagnostics Holdings, Inc. 8K

The 8-K furnishes an investor presentation outlining Cardio Diagnostics Holdings, Inc.’s precision cardiovascular testing business, IP, commercialization, reimbursement progress, and growth strategy.

Cardio Diagnostics Holdings, Inc. used the Form 8-K to furnish an investor presentation (Exhibit 99.1) describing its AI- and epigenetics-based cardiovascular diagnostic platform, including its Epi+Gen CHD and PrecisionCHD blood tests, commercialization strategy, intellectual property portfolio, emerging clinical and economic evidence, recent operational progress such as initiating in-house processing at a company-owned CLIA laboratory to reduce costs and increase capacity, and key reimbursement milestones such as assignment of PLA CPT codes, CMS final payment rates of $854 per test, initial commercial in-network coverage and out-of-network billing capabilities, and its ongoing efforts to secure broader Medicare and commercial payer coverage and international distribution partnerships.

Filing Facts

CIK

1870144

Ticker

-

Form

8K

Source Type

sec

Accession

0001079973-26-001153

Alert Tier

5